Defence Therapeutics Inc.
DTCFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.33 | 0.47 | -2.05 | -0.24 |
| FCF Yield | -1.92% | 0.00% | -2.83% | -2.62% |
| EV / EBITDA | -64.81 | -107.34 | -82.11 | -39.37 |
| Quality | ||||
| ROIC | -38.80% | -444.62% | -87.66% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.03 | 0.71 | 2.10 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 100.00% | -198.62% | -864.67% |
| Safety | ||||
| Net Debt / EBITDA | -1.07 | -0.69 | 0.81 | -1.70 |
| Interest Coverage | -50.89 | -50.94 | -12.33 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |